Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 6/2019

28.03.2019 | Original Article – Cancer Research

ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data

verfasst von: Young Wha Koh, Jae-Ho Han, Seokjin Haam, Joonho Jung

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer stem cells (CSC) and epithelial–mesenchymal transition (EMT) pathways are crucial for cancer progression. However, synergistic interactions between CSC and EMT are not clear in non-small cell lung cancer (NSCLC). The objective of this study was to investigate CSC markers such as CD44, NANOG, and ALDH1 expression and its correlation with EMT markers in NSCLC patients. Its association with survival was also determined.

Methods

CD44, NANOG, and ALDH1 protein expression was evaluated in 267 resected NSCLC and its correlation with e-cadherin, β-catenin, p120 catenin, vimentin, SNAIL, and TWIST expressions was determined based on immunohistochemical and mRNA expression data from The Cancer Genome Atlas (TCGA) database. Survival analyses also were performed based on immunohistochemistry and mRNA expression data from Gene Expression Omnibus dataset.

Results

ALDH1 expression in lung adenocarcinoma was positively correlated with the epithelial-like phenotype, low vimentin and low TWIST in immunohistochemical and mRNA expression data. NANOG and ALDH1 expressions measured by immunohistochemical and mRNA expression profiling data of adenocarcinomas were associated with a favorable prognosis. ALDH1 was an independent favorable prognostic marker for overall survival or recurrence-free survival in adenocarcinoma (P = 0.026 and P = 0.033, respectively). The epithelial-like phenotype expressing P120-catenin and beta-catenin was associated with a favorable prognosis; however, the TWIST-expressing mesenchymal-like phenotype was correlated with an unfavorable prognosis.

Conclusions

NANOG and ALDH1 protein or mRNA expression showed improved prognosis in adenocarcinoma alone. ALDH1 expression correlated with an epithelial-like phenotype.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Ettinger DS et al (2017) Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 15:504–535CrossRef Ettinger DS et al (2017) Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 15:504–535CrossRef
Zurück zum Zitat McCarty KS Jr et al (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Can Res 46:4244s–4248s McCarty KS Jr et al (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Can Res 46:4244s–4248s
Zurück zum Zitat Sung WJ, Park KS, Kwak SG, Hyun DS, Jang JS, Park KK (2015) Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis. Int J Clin Exp Pathol 8:8997–9009PubMedPubMedCentral Sung WJ, Park KS, Kwak SG, Hyun DS, Jang JS, Park KK (2015) Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis. Int J Clin Exp Pathol 8:8997–9009PubMedPubMedCentral
Metadaten
Titel
ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data
verfasst von
Young Wha Koh
Jae-Ho Han
Seokjin Haam
Joonho Jung
Publikationsdatum
28.03.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-019-02906-2

Weitere Artikel der Ausgabe 6/2019

Journal of Cancer Research and Clinical Oncology 6/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.